arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PROCEPT BioRobotics Corp

PRCT
$18.43 ▼ -0.07 (-0.38%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

PROCEPT BioRobotics Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.1B
Dividend Yield
Revenue Growth 19.3%
Op. Margin -29.0%
ROIC -7.0%
FCF / Share $-0.39
Trailing P/E
Price / Book 3.1x
FCF Yield
Debt / Equity 0.15
info Valuation on last close. End-of-day price, Sep 22, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$94.50M
↑ +19.3%
Net Income Profit after all expenses
$-31.64M
↓ -27.9%
Operating Margin Operating profit as % of sales
-29.0%
↑ +26.1% 7th
FCF / Share Free cash flow per share
$-0.39
↓ -20.9%
Long-Term Debt Long-term obligations
$51.72M
— +0.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
8
Returns
25
Financial Health
50
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters